SavedAdd your journal

Journals / Astım Allerji İmmünoloji / 2012 / Cilt: 10 - Sayı: 2

ACE inhibitörleri venom immünoterapisi alan hastalarda gerçekten güvenli midir?

Are ACE inhibitors realy safe in the patients receiving venom immunotherapy?

Mehmet ÜNSEL
F. Ömür ARDENİZ
Nihal METE
Z. Aytül SİN
Pages
100–103
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein we reported a case experienced anaphylaxis after being put on angiotensin corverting enzyme (ACE) inhibitor and beta-blocker therapy by reason of heart at- tack while receiving venom immunotherapy injections with Apis mellifera in the maintenance phase and discussed the likely causitive factors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Few reports have been notified regarding systemic allergic reactions in patients being put on angi-otensin corverting enzyme (ACE) inhibitor du- ring the course of venom immunotherapy.
📊
Key Findings & Data:There have been conflicting suggestions with respect to ACE inhibitor use during the course of VI in the literature.
💡
Conclusion & Impact:Herein we reported a case experienced anaphylaxis after being put on angiotensin corverting enzyme (ACE) inhibitor and beta-blocker therapy by reason of heart at- tack while receiving venom immunotherapy injections with Apis mellifera in the maintenance phase and discussed the likely causitive factors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Few reports have been notified regarding systemic allergic reactions in patients being put on angi-otensin corverting enzyme (ACE) inhibitor du- ring the course of venom immunotherapy. There have been conflicting suggestions with respect to ACE inhibitor use during the course of VI in the literature. There is no consensus report clarifying this issue in the clinical practice. Herein we reported a case experienced anaphylaxis after being put on angiotensin corverting enzyme (ACE) inhibitor and beta-blocker therapy by reason of heart at- tack while receiving venom immunotherapy injections with Apis mellifera in the maintenance phase and discussed the likely causitive factors.

Özet

Venom immünoterapisi sırasında anjiyotensin dönüştürücü enzim (ACE) inhibitörü başlandıktan sonra sistemik allerjik reaksiyon gelişimini bildiren olgu sunumları mevcuttur. Literatürde bu hastalarda ACE inhibitörü kullanımına ilişkin birbiriyle çelişen öneriler bulunmaktadır. Burada, Apis mellifera ile venom immünoterapisi almakta olan hastada idame fazında iken, kalp krizi nedeniyle ACE inhibitörü ve beta-bloker başlandıktan sonra sistemik allerjik reaksiyon gelişen bir olgu sunuldu. Ayrıca, sistemik allerjik reaksiyon gelişimine zemin hazırlayan olası mekanizmalar tartışıldı.

🔖

Cite This Article

ÜNSEL, M., ARDENİZ, F. Ö., METE, N., SİN, Z. A. (2012). ACE inhibitörleri venom immünoterapisi alan hastalarda gerçekten güvenli midir?. Astım Allerji İmmünoloji, Cilt: 10 - Sayı: 2, 100–103. https://ajindex.com/articles/160507

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Ober AI, MacLean JA, Hannaway PJ. Life-threatining anaphylaxis to venom immunotherapy in a patient ta- king an angiotensin-converting enzyme inhibitor (let- ter). J Allergy Clin Immunol 2002;112:1008-9
  2. Tunon-de-Lara JM, Villanueva P, Marcos M, Taytard A. ACE inhibitors and anaphylactoid reactions during venom immunotherapy. Lancet 1992;340:908
  3. White KM, England RW. Safety of angiotensin-conver- ting enzyme inhibitors while receiving venom immunot- herapy. Ann Allergy Asthma Immunol 2008;101:426- 30
  4. Kemp SF, Lieberman P. Inhibitors of angiotensin II: potential hazards for patients at risk for anaphylaxis? Ann Allergy Asthma Immunol 1997;78:527-9
  5. Stumpf JL, Shehab N, Patel AC. Safety of angiotensin- converting enzyme inhibitors in patients with insect venom allergies. Ann Pharmacother 2006;40:699- 703
  6. Golden DB, Moffitt J, Nicklas RA, Freeman T, Graft DF, Reisman RE, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Im- munol 2011;127:852-4
  7. Ring J, Messmer K. Incidence and severity of anaphy- lactoid reactions to colloid volume substitutes. Lancet 1977;1:466-9
  8. Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude-Eberink JN. EAACI Interest Group on Insect Venom Hypersen- sitivity. Diagnosis of Hymenoptera venom allergy. Al- lergy 2005;60:1339-49
  9. Nishimura H, Alhenc-Gelas F, White A. Activation of membrane-bound kallikrein and renin in the kidney. Proc Natl Acad Sci USA 1980;77:4975-8
  10. Bandeira-Melo C, Calheiros AS, Silva PM,Cordeiro RS, Teixeira MM, Martins MA. Suppressive effect of dis- tinct bradykinin B2 receptor antagonist on allergenevoked exudation and leukocyte infiltration in sensitized rats. Br J Pharmacol 1999;127:315-20
  11. Imamura T, Dubin A, Moore W, Tanaka R, Travis J. Induction of vascular permeability enhancement by human tryptase: dependence on activation of prekallikrein and direct release of bradykinin from kininogens. Lab Invest 1996;74:861-70
  12. Gökmen NM. Venom biochemistry. Türkiye Klinikleri J Allergy-Special Topics 2008;1:22-5
  13. Aoki J, Inoue A, Makide K, Saiki N, Arai H. Structure and function of extracellular phospholipase A1 belon- ging to pancreatic lipase gene family. Biochimie 2007;89:197-204
  14. Konno K, Palma MS, Hitara IY, Juliano MA, Juliano L, Yasuhara T. Identification of bradykinins in solitary wasp venoms. Toxicon 2002;40:309-12
  15. Neuman I, Ishay JS, Creter D. Hyperreactivity to bee stings: reevaluation. Ann Allergy 1983;50:410-2
  16. Herma